NCT01682902 - A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes | Biotech Hunter

Enrollment

43

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

Faster-acting insulin aspart

Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.

DRUG

Faster-acting insulin aspart

Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.

DRUG

insulin aspart

Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.

Trial Locations (1)

30318

Novo Nordisk Investigational Site, Atlanta